Back to All

Diaceutics Convenes Pharmaceutical and Diagnostic Industry Leaders to Identify Financial Benchmarks Essential to Successful Co-Development of Personalized Medicine

1 May, 2010

Diaceutics has brought together leaders from the pharmaceutical and diagnostic industries to identify financial benchmarks crucial for successful co-development of personalized medicine. This collaborative effort aims to establish clear financial guidelines to optimize the co-development process and ensure its success.

By convening key stakeholders, Diaceutics is fostering collaboration and knowledge exchange to address challenges and opportunities in personalized medicine co-development. The establishment of financial benchmarks will provide valuable insights and guidance for companies navigating the complex landscape of personalized medicine.

Stay informed about the outcomes of this collaboration as Diaceutics continues to drive progress and innovation in the field of personalized medicine co-development.

Click here to view the full article

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny